Commercialization cost sharing payments income (expense) under collaboration agreement.

No definition available.

Name:	mdvn_CommercializationCostSharingPaymentsIncomeExpense
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development cost sharing payments income (expense) under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_DevelopmentCostSharingPaymentsIncomeExpense
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of net sales of XTANDI in the United States, pursuant to collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfNetSalesUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Share percentage of development and commercialization cost under collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_SharePercentageOfDevelopmentAndCommercializationCostUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

+ Details

Name:	us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=mdvn_AstellasPharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_InvestmentTypeAxis=mdvn_AmortizationOfDeferredUpfrontAndDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_DevelopmentCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_ParentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=mdvn_CommercialCostSharingPaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration Agreement - Collaboration Revenue and Collaboration Receivables - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaboration revenue percentage of U.S. XTANDI net sales	50.00%	50.00%	50.00%	50.00%
Amortization of deferred upfront and development milestones		$ 846		$ 2,257
Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Development cost-sharing payments	$ 15,100	17,600	$ 28,400	31,400
Commercialization cost-sharing payments	$ 4,500	2,700	$ 23,300	22,800
Astellas Pharma Inc. [Member] \| Amortization of deferred upfront and development milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amortization of deferred upfront and development milestones		$ 846		$ 2,257
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs			50.00%
Development cost-sharing payments [Member] \| Collaborative agreement [Member] \| Medivation Inc [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs			33.33%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs			50.00%
Commercial cost sharing-payments [Member] \| Astellas Pharma Inc. [Member] \| Collaborative agreement [Member] \| ex-U.S. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of XTANDI development and commercialization costs			66.67%